Cure51 Joins Worldwide Innovative Network (WIN) in Personalized Cancer Medicine Consortium

By , in France on . Tagged width: ,

Cure51 and Worldwide Innovative Network (WIN), in personalized cancer medicine consortium have joined forces to bring cancer research to a new level, rallying the brightest oncologists, and academics in the world and leveraging data, cutting edge precision tech to make cancer a disease of the past. WIN Consortium is a network of 39 world-class academic medical centers, industries, research organizations and patient advocates spanning 19 countries and 5 continents.

We are excited to welcome Cure51 to WIN and we look forward to working with their focused, inspired and dynamic teams.

said Prof. Wafik S. El-Deiry, Chair of WIN Consortium, and Director, Legorreta Cancer Center, Associate Dean, Oncologic Sciences, Warren Alpert Medical School, Brown University.

Investigating exceptional cancer survivors is a brilliant idea and WIN network can contribute to this endeavor with our global footprint.

said Dr Razelle Kurzrock, Chief Medical Officer of WIN, Professor of Medicine, Associate Director Clinical Research, MCW Cancer Center and Linda T. & John A. Mellowes Chair of Precision Oncology. 

Simon Istolainen and Nicolas Wolikow, co-founders of Cure51
Simon Istolainen and Nicolas Wolikow, co-founders of Cure51

We are on a tireless mission to impact cancer in the next 10 years, and the partnership with WIN is a huge step in the right direction.

We believe that cancer is a disease of the past, and with the best medical institutes in the world, we are building the tech to prove it. In a matter of years, we want every patient to become a miraculous survivor.
Today, depending on the type of cancer 0.5% to 2% of patients survive aggressive cancers; we’re building a database of survivors to crack the survival code, which we know exists in nature, and drastically increase this ratio.

says Cure51 co-founder Simon Istolainen.